182 related articles for article (PubMed ID: 8842048)
21. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Didier A; Wenger J; Loor F
Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477
[TBL] [Abstract][Full Text] [Related]
22. Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833.
Kimchi-Sarfaty C; Kasir J; Ambudkar SV; Rahamimoff H
J Biol Chem; 2002 Jan; 277(4):2505-10. PubMed ID: 11700317
[TBL] [Abstract][Full Text] [Related]
23. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
[TBL] [Abstract][Full Text] [Related]
24. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788.
Demmer A; Dunn T; Hoof T; Kubesch P; Tümmler B
Eur J Pharmacol; 1996 Nov; 315(3):339-43. PubMed ID: 8982674
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
[TBL] [Abstract][Full Text] [Related]
28. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.
Kim WJ; Kakehi Y; Hirai M; Arao S; Hiai H; Fukumoto M; Yoshida O
Jpn J Cancer Res; 1995 Oct; 86(10):969-77. PubMed ID: 7493917
[TBL] [Abstract][Full Text] [Related]
31. Reduced cyclosporin accumulation in multidrug-resistant cells.
Goldberg H; Ling V; Wong PY; Skorecki K
Biochem Biophys Res Commun; 1988 Apr; 152(2):552-8. PubMed ID: 2896500
[TBL] [Abstract][Full Text] [Related]
32. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Ito T; Yano I; Tanaka K; Inui KI
J Pharmacol Exp Ther; 1997 Aug; 282(2):955-60. PubMed ID: 9262363
[TBL] [Abstract][Full Text] [Related]
33. Purification and reconstitution of functional human P-glycoprotein.
Ambudkar SV
J Bioenerg Biomembr; 1995 Feb; 27(1):23-9. PubMed ID: 7629047
[TBL] [Abstract][Full Text] [Related]
34. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells.
Tamai I; Safa AR
J Biol Chem; 1990 Sep; 265(27):16509-13. PubMed ID: 1975813
[TBL] [Abstract][Full Text] [Related]
35. In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).
Oda K; Nemoto H; Nagasaka Y; Kawamura A; Usui T
Biopharm Drug Dispos; 2014 Apr; 35(3):135-44. PubMed ID: 24822242
[TBL] [Abstract][Full Text] [Related]
36. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
37. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
38. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract][Full Text] [Related]
39. Drug accumulation in the presence of the multidrug resistance pump: dissociation between verapamil accumulation and the action of P-glycoprotein.
Ayesh S; Litman T; Stein WD
Recept Channels; 1997; 5(3-4):175-83. PubMed ID: 9606721
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein.
Horton JK; Thimmaiah KN; Altenberg GA; Castro AF; Germain GS; Gowda GK; Houghton PJ
Mol Pharmacol; 1997 Dec; 52(6):948-57. PubMed ID: 9415704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
